Merck said its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients failed to meet the primary endpoint in a mid-stage study. The results mark another setback in the field of an emerging class of so-called anti-TIGIT therapies that have triggered a flurry of research and deal activity.